SCN SIGNS MARKET MAKER AGREEMENTS

(NGM:SCN)

Scandinavian Clinical Nutrition (SCN) has entered into Market Making Agreements for the company’s shares with Orion Securities ASA in Norway and Mangold Fondkommission AB in Sweden.

The purpose of the agreements is to increase the liquidity of the shares of the company, which are listed on Oslo Axess in Norway and on NGM Equity in Sweden. The agreements are in accordance with the standard requirements of the Oslo Stock Exchange and NGM, and will take effect as of today, June 5, 2008.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).